Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During Orthopedic Surgeries in Egyptian Patients.

A randomized controlled trial on adults who underwent orthopedic surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in the orthopedic surgical population.

Eligible patients will be randomized in a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Surgical Site Infection (SSI) Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Surgical Wound Infection Wound Infection

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Orthopaedic surgical ward patients who underwent major surgery.

Exclusion criteria

Patients who require reoperation within 30 days.
Immunosuppressant patients.
Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
Pregnancy or breastfeeding.

Treatment and study plan

Cefazolin 2 g Infusion

Drug

Intraoperative continuous infusion (CI) of cefazolin

Cefazolin 2 GM Injection

Drug

Administration of cefazolin 2 gm 30 minutes pre-surgery

Primary outcomes

Incidence of surgical site infection

Time frame: within 90 days after surgery.

To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in the orthopedic surgical population.

Study contacts

Contact information is provided by the study sponsor or research team.

Heba A Abdeen

CONTACT

[email protected]

0201003403231

Sponsors and collaborators

Lead sponsor

Helwan University

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Jun 18, 2026
Registry last updated: Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting